Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out.
Proto C, Ferrara R, Signorelli D, Lo Russo G, Galli G, Imbimbo M, Prelaj A, Zilembo N, Ganzinelli M, Pallavicini LM, De Simone I, Colombo MP, Sica A, Torri V, Garassino MC.
Proto C, et al. Among authors: ferrara r.
Cancer Treat Rev. 2019 May;75:39-51. doi: 10.1016/j.ctrv.2019.03.004. Epub 2019 Mar 28.
Cancer Treat Rev. 2019.
PMID: 30954906
Free article.
Review.